The role of [131I]metaiodobenzylguanidine in the treatment of medullary thyroid carcinoma: results in five cases.

@article{Troncone1991TheRO,
  title={The role of [131I]metaiodobenzylguanidine in the treatment of medullary thyroid carcinoma: results in five cases.},
  author={Luigi Troncone and Vittoria Rufini and Maria Lodovica Maussier and Venanzio Valenza and M S Daidone and Stefano Luzi and Michela De Santis},
  journal={Journal of nuclear biology and medicine},
  year={1991},
  volume={35 4},
  pages={327-31}
}
Therapeutic doses of [131I]metaiodobenzylguanidine (131I-MIBG) were administered to 5 patients, 3 men and 2 women aged from 33 to 66 years, with proven medullary thyroid carcinoma (one "intermediate" papillary/medullary tumor). The treatment procedure consisted of single doses (3.7-8.5 GBq) of 131I-MIBG given by slow i.v. infusion at 2-8 month intervals. In two advanced-stage patients the treatment played an important palliative role, ranging from an objective response (substantial, but not… CONTINUE READING